by Stacey B. Trooskin, Helen Reynolds, and Jay R. Kostman
Clin Infect Dis 2015 61: 1825-1830
Several breakthrough hepatitis C drugs received Food and Drug Administration approval in 2014, with cure rates exceeding 90%. These drugs are being rationed, due to costs. The authors propose an AIDS Drug Assistance Program analogue and cost-control mechanisms to facilitate treatment.